Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4352633 | 0.87 | KDM4E (0.39) | RIPK1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL1274248 | 0.87 | KDM4E (0.39) | RIPK1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL7244883 | 0.84 | OPRM1 (0.41) | MEN1KMT2A | |
| SCHEMBL7244888 | 0.84 | OPRM1 (0.41) | MEN1KMT2A | |
| SCHEMBL3340453 | 0.84 | TDP1 (0.38) | TDP1RIPK1HPGDALDH1A1KDM4E | |
| SCHEMBL3338985 | 0.84 | TDP1 (0.38) | TDP1RIPK1HPGDALDH1A1KDM4E | |
| SCHEMBL5862818 | 0.83 | BMP1 (0.41) | TDP1HPGDALDH1A1NPSR1KMT2A | |
| SCHEMBL3338164 | 0.82 | TDP1 (0.38) | TDP1RIPK1HPGDALDH1A1KDM4E | |
| SCHEMBL4425980 | 0.75 | AOC3 (0.40) | TDP1KMT2AHTTAOC3 | |
| SCHEMBL5336763 | 0.74 | SMN1; SMN2 (0.50) | RIPK1ALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTRAZENECA R&D (SE) | 2010-06-17 | — | — | US | disclosed |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152219-A1 | PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | LTK, ERBB2, ERBB3 | TDP1 1537/4885RIPK1 332/4885HPGD 3241/4885 |
| US-20070142413-A1 | Pyrazole derivatives as inhibitors of receptor tyrosone kinases | PRKDC, MUSK, LTK | TDP1 593/4885RIPK1 368/4885HPGD 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.